

(Leave blank)

W81XWH-08-1-0467

 \acute{A}

TITLE:

Characterization of the Truncated Androgen Receptor Generated by Calpain-Dependent Proteolysis in Prostate Cancer

 \hat{A}

PRINCIPAL INVESTIGATOR:

Honglin Chen Ph.D.

 \dot{A}

CONTRACTING ORGANIZATION:

University of California Davis
Davis, CA 95616

 \dot{A}

REPORT DATE:

August 2009

TYPE OF REPORT:

Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

X Approved for public release; distribution unlimited

Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 8/31/09		2. REPORT TYPE Annual Summary		3. DATES COVERED 1 AUG 2008 - 31 JUL 2009	
4. TITLE AND SUBTITLE Characterization of the Truncated Androgen Receptor Generated by Calpain-Dependent Proteolysis in Prostate Cancer				5a. CONTRACT NUMBER W81XWH-08-1-0467	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Honglin Chen Ph.D. Email: hlchen@ucdavis.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California Davis Davis, CA 95616				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT <p>Androgen ablation therapy is effective in treating androgen-dependent prostate tumors; however, tumors that can proliferate in castrate levels of androgen eventually arise. We previously reported that in CWR22Rv1 (Rv1) cells, the protease calpain 2 can cleave the androgen receptor (AR) into a constitutively active ~80 kDa low molecular weight (LMW) form. In this study, we further dissect the mechanisms that produce the AR LMW forms using Rv1 cells and the related CWR22-R1 (R1) cells. The 39 a.a. insertional mutation in Rv1 cells sensitizes this AR (E3DM-AR) calpain 2 proteolysis. R1 cells encode the same AR molecule as the parental CWR22 xenograft. Using anti-calpain 2 siRNA and calpeptin, we find that calpain 2 plays a role in the generation of the LMW-AR in R1 cells. Furthermore, LMW-AR expression is regulated by the activation of calpain 2 by Extracellular Signal-Regulated Kinases 1/2 (ERK). Inhibition of ERK phosphorylation or siRNA-mediate decrease of ERK expression reduces LMW-AR levels in R1 cells. Conversely, activation of the MAPK pathway and increased ERK phosphorylation results in increased levels of LMW-AR. Finally, analyses of human tumor samples found that LMW-AR levels are higher in tumors that have an increased calpain/calpastatin ratio and/or increased levels of phospho-ERK (pERK), suggesting that a higher calpain/calpastatin ratio collaborates with activation of the MAP kinase pathway to promote the generation of the LMW-AR. Furthermore, cellular localization analysis of AR shows that the LMW-AR is the predominant form (~90%) present in the nucleus in Rv1 cells cultured in the absence of androgen, allowing us to study the chromosomal binding sites of LMW-AR using chromatin immunoprecipitation (ChIP) combined with DNA microarray analysis (ChIP-on-chip). Using a human promoter array, a total of 128 potential LMW-AR chromosomal binding sites are identified in the absence of androgen and they are also present in the presence of androgen. We find that the majority of the binding sites contain no AR-responsive elements (AREs) and are distant (>2kb) from the transcriptional start sites. Corresponding expression array studies identify that only a subset of genes in the vicinity of LMW-AR binding sites respond to the stimulation of dihydrotestosterone (DHT). Moreover, quantitative RT-PCR analysis shows that LMW-AR can transcriptoinally regulate certain genes in a different manner as full-length (FL) AR.</p>					
15. SUBJECT TERMS low-molecular weight androgen receptor, full-length androgen receptor, calpain, ERK, calpastatin, Chip-on-Chip					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	29	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	6
Body.....	8
Key Research Accomplishments.....	13
Reportable Outcomes.....	14
Conclusion.....	15
References.....	16
Supporting Data.....	19

Introduction

Prostate cancers are a commonly diagnosed malignancy that is treated with hormonal therapy aimed at blocking signaling through the AR. Initially most prostate cancers present are androgen-dependent neoplasms, thus the clinical response is positive. Unfortunately, aggressive cancers that proliferate in castrate levels of androgens eventually develop. Analysis of clinical relapsed tumor revealed that over 90% express the AR [1-4]. The AR is central to the initiation and growth of prostate cancers and in their responses to therapy. The AR is a member of the steroid hormone superfamily of ligand-activated transcription factors that include the progesterone and glucocorticoid receptors [5, 6], and contains four functional domains: an N-terminal regulatory region, a DNA-binding domain (DBD), a hinge domain and a ligand binding domain (LBD) [7]. In the absence of ligand, the AR is retained in the cytoplasm. The binding of hormone to the LBD alters AR conformation promoting dimerization, phosphorylation, and translocation into the nucleus, allowing for the recruitment of proteins into the transcription initiation complex [6, 8, 9].

During tumor progression, tumors acquire the ability to proliferate in castrate levels of androgen. Alterations of AR have been postulated to account for the aberrant AR activation and acquisition of proliferative capabilities in reduced levels of androgen. Studies have shown that 25-30% of androgen independent tumors that arose following endocrine therapy have an amplification of the AR gene [10, 11]. AR mutations are more common in androgen independent cancers [12, 13]. In most cases, AR mutations broaden ligand specificity so that mutated AR can be activated more efficiently by various steroids [7]. The well studied androgen responsive cell lines LNCaP and MDA PCa have mutations in the LBD that broadens the ligand specificity, allowing for activation by estrogens, progesterone, glucocorticoids and adrenal androgens [14-16]. The CWR22 xenograft has a mutation in the LBD that enhances responsiveness to estradiol and progesterone [17]. Structure function analysis of the AR showed that deletion of the LBD generates a constitutively active molecule [18]. This *in vitro* analysis was validated by a report which described a point mutation at Q640 that resulted in a C-terminally truncated and constitutively active AR [19]. The latter studies imply that AR truncation may be a mechanism in the etiology of androgen independent tumors. Others and we previously reported that the calpain protease could cleave the AR molecule to LMW isoforms [20-22], including a ~80 KDa C-terminally truncated. We also reported that ~ 80KDa LMW-AR is present in some human prostate tumors [21]. Using the androgen-independent cell line model CWR22Rv1 expressing high level of the LMW-AR, we have shown that inhibition of calpain activity induces apoptosis in the cells cultured in the absence of androgen and statistically-significant inhibition of tumor growth in castrated CWR22rv1 xenografts. These studies implicate that the LMW-AR generated by calpain-dependent proteolysis of the AR may play an important role in conferring androgen-independence in a subset of prostate cancer [21].

ChIP-on-chip has recently emerged as the staple of studying genome-wide chromosomal binding sites of transcription factors and identifying their novel targets [23, 24]. Despite the well-characterized androgen response elements (AREs) in the promoter and enhancer of prostate-specific antigen (PSA), little is known about AR *cis*-regulatory sites across the human genome. Wang et al., [25] used a tiling DNA microarray combined with ChIP to map the AR binding regions on chromosome 21 and 22 in androgen-dependant LNCaP cells. In the 90 AR binding sites identified on the two chromosomes, they reported that the majority AR binding regions contain noncanonical AREs and are far (>10kb) from the transcriptional start sites of androgen-regulated genes. Another group performed ChIP-on-chip in LNCaP cells using a sampler DNA microarray called ENCODE chip which represents approximately 1% of the whole genome [26]. They found that most of the AR-interacting regions are located in non-

promoter proximal regions. Interestingly, similar results have been shown on the binding sites of estrogen receptor (ER), another ligand-dependant nuclear receptor [27]. These studies indicate the complexity of the *cis*-regulation by these nuclear receptor transcription factors.

Two cell lines, CWR22Rv1 (Rv1) and CWR22R1 (R1), that proliferate in castrate levels of androgens were isolated in two laboratories from CWR22 relapse tumors. CWR22, an androgen-dependent, serially transplantable xenograft model was derived from a primary human prostate cancer and recapitulates salient feature of prostate cancer progression in patients [28]. The AR in the CWR22 xenograft has a mutation (H847Y) in the LBD of the molecule [17]. Like parental CWR22 cells, Rv1 and R1 cells express the AR containing the point mutation, while Rv1 AR also contains a duplication of DBD encoding exon3, which results in an insertion of 39 additional amino acids [29]. A previous study found that the R1 cell line also expresses a ~80KDa LMW AR isoform, but to a less extent than Rv1 cells [30]. The mechanism resulting in the expression of the LMW-AR in R1 cells has not been reported.

Body

There are some deviations from the original Statement of Work (SOW). After the submission of the application, we were able to obtain an additional line CWR22R1 (R1) which also express the LMW-AR. Therefore, we were interested in investigating whether the mechanism leading to the generation of LMW-AR in R1 cells are different from that of Rv1 cells. This part of study was not in the original SOW. Also, in the original SOW, we planned to use these two artificial sublines of CWR22Rv1 (CWR22rv1-fl-AR expressing exogenous fl-AR only and CWR22rv1-tr- AR expressing exogenous tr-AR only) to study the DNA binding pattern and gene expression profiles of LMW-AR and fl-AR. During the research, we found that the LMW-AR is the predominant form (~90%) present in the nucleus in Rv1 cells cultured in the absence of androgen, which allows the study of the potential LMW-AR specific chromosomal binding sites. Using this native cell model is a better approach than artificial sublines for this study purpose. In summary, we have expanded the tasks listed in SOW. So far, the task 1 and 2 listed in SOW has almost be completed. Task 3 and 4 haven't been conducted. Following is the results completed in this time period.

Characteristics of the Rv1 and R1 cell lines.

Two castrate resistant cells lines, R1 and Rv1, were derived from two independent CWR22 relapsed tumors. The cellular phenotypes of the Rv1 and R1 cells are similar. In the presence of androgen the cells tend to grow in clusters, while in the absence of androgens they tend to be more scattered and less adhesive (Figure 1A). The AR in both lines has the same LBD mutation as the CWR22 xenograft [17]. As previously reported, R1 and Rv1 cells express the LMW AR forms [29, 31] (Figure 1B). Western immunoblot analysis indicated that R1 cells expressed higher levels of AR than Rv1 cells, but the ratio of the LMW to full length (FL)-AR was higher in Rv1 cells. The size of the FL-AR in the R1 cells is smaller than the FL-AR in the Rv1 cells, since R1 cells do not have the 39 amino acid duplication of exon 3. Closer inspection revealed that the ~80 KDa LMW forms could be resolved into several discrete bands (Figure 1B). The MTS proliferation assay confirmed that the R1 and Rv1 cell proliferation rates were only slightly slower in androgen-depleted media compared to the cell proliferation rates in the presence of androgen (Figure 1C). The proliferation assay conducted in the presence of 10 uM Casodex indicated that R1 and Rv1 cells were refractory to the inhibitory effects of this AR inhibitor (Figure 1D). While all three lines are responsive to androgen, only LNCaP cells are dependent on androgen to sustain growth.

Generation of the LMW-AR involves calpain.

We have reported previously that the inhibition of calpain activity by calpeptin reduces the levels of the expression of the LMW-AR in Rv1 cells [21]. Likewise, treatment of R1 cells proliferating in the presence or absence of androgen (Ad) with the calpeptin reduced the level of LMW-AR in R1 cells (Figure 2A). We previously showed that proteolysis of the calpain substrate focal adhesion kinase (FAK) is a good indicator of calpain activity [32]. Calpeptin treatment of R1 cells reduced the levels of LMW-FAK (Figure 2A). To further analyze the role of calpain in the generation of LMW-AR, calpain 2 expression was analyzed in several prostate tumor derived, as well as immortalized, prostate cell lines. R1 cell expressed much higher levels of calpain 2 than Rv1 and LNCaP cells (Figure 2B). Interestingly, the two AR negative and highly metastatic cells lines PC3 and DU145 expressed the highest levels of calpain 2. Given that calpain activity is regulated by its endogenous inhibitor calpastatin, we analyzed calpastatin levels as well, and found that expression was comparable in all the cell lines (Figure 2B). R1 cells had higher amounts of proteolyzed FAK, indicating greater calpain activity (Figure 2C). The

extent of FAK cleavage was greater in the absence of androgen, suggesting that calpain activity may be higher under androgen-depleted conditions. To further confirm the involvement of calpain 2 in the generation of the LMW-AR forms in R1 cells, we used anti-calpain 2 siRNA to reduce the calpain 2 expression. A previous study reported that calpain 2 has a very long half life of 5 days [33]. A 6-day treatment resulted in an ~60% reduction of calpain 2 protein level in R1 cells (Figure 2D) and reduced levels of the LMW-AR forms (Figure 2D). This treatment also reduced FAK proteolysis indicating that calpain 2 activity was reduced. This analysis indicates that calpain 2 plays a role in the generation of the LMW-AR in R1 cells.

R1 cell proliferation is not androgen dependent, however, R1 cells are androgen responsive since the expression of certain genes is androgen regulated. We found that the expression of claudin 4 (CLDN4) is highly repressed by the addition of androgen (Figure 2E). If calpeptin treatment reduces the levels of LMW-AR, then in the absence of androgen the expression of androgen repressed genes may be further activated. Calpeptin treatment of R1 cells further increased the expression of CLDN4, thus arguing the LMW-AR has a role in transcription of certain genes.

The exon3 duplication sensitizes Rv1 AR to calpain proteolysis

Rv1 cells express higher levels of the LMW-AR but have low expression of calpain 2 protein and calpain activity (Figure 2). We hypothesize that the exon 3 duplication sensitizes the E3DM-AR to calpain cleavage. The AR-null PC3 cells expressing high levels of calpain 2 were transfected with cDNAs plasmids encoding either the wildtype or E3DM-AR. As expected, the E3DM-AR was slightly larger than the wildtype receptor (Figure 3A). Additionally, the LMW forms expressed in cells transfected with the E3DM-AR were larger than the LMW forms expressed in cells transfected with the wildtype AR cDNA. To test the hypothesis that the E3DM-AR is more sensitive to calpain-dependent proteolysis, extracts prepared from the transfected cells were treated with CaCl_2 to activate the endogenous calpain activity. As shown in Figure 3B, the AR was progressively cleaved into the smaller forms by the addition of CaCl_2 . The inclusion of calpeptin retarded proteolysis, indicating that proteolysis was calpain dependent (figure 3B). While the ~80 KDa forms were present initially and throughout the time course, as proteolysis progressed, the LMW-AR was further proteolyzed to smaller peptides. In vivo, the ~ 80 KDa LMW-AR forms that are generated by proteolysis can translocate into the nucleus, where they would be less susceptible to further proteolysis. In vitro, as was previously observed [20] activated calpain proteolyzes the AR to still smaller forms. The mutant E3DM-AR was cleaved more rapidly than the wildtype FL-AR, resulting in the disappearance of the FL-AR (compare lanes 4 and 9).

The expression of the LMW-AR is regulated by the ERK kinase

Calpain activity is tightly regulated by various mechanisms, including phosphorylation. Previous studies have shown that ERK can phosphorylate calpain 2 to stimulate protease activity [34]. ERK expression was analyzed in immortalized (RWPE-1, PZ-HPV-7 and pRNS-1-1) and tumor derived (PC3, LNCaP, Rv1, R1 and DU145) cell lines. All of the tumor derived cells lines had higher levels of ERK in comparison to the immortalized cell lines (Figure 4A). A comparison of R1 and Rv1 cells proliferating in the absence and presence of androgen showed that R1 cells had higher levels of the active form of the protein (pERK) under both conditions (Figure 4B).

ERK is phosphorylated and activated by MEK, a dual threonine and tyrosine kinase [34]. Treatment of R1 cells with the MEK inhibitor U0126 for 24 or 48 hours reduced ERK phosphorylation (Figure 4C). An analysis of the AR in the same extracts (Figure 4C) indicated

that inhibition of ERK activity reduced the levels of LMW-AR. Similar results were found in Rv1 cells (data not shown). To confirm that LMW-AR expression is dependent on ERK, cells were treated with control siRNA and ERK siRNA. Inhibition of ERK expression resulted in decreased levels of LMW-AR (Figure 4D). This analysis established that ERK activation has a role in the etiology of the LMW-AR forms.

Since the PKC activator phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) can result in ERK phosphorylation [35], Rv1 and R1 cells were treated with TPA in the absence of androgen for 1 or 2 hours to stimulate ERK activity. This treatment promoted an increase in levels of the LMW-AR indicating that activation of this pathway resulted in enhanced AR proteolysis (Figure 5A). TPA treatment of Rv1 cells also resulted in decreased levels of the FL-AR; after a 2 hour TPA treatment the FL-AR was barely discernable, arguing that in vivo, as in vitro, the Rv1 AR is more sensitive to proteolysis.

To test our hypothesis that an increase in calpain 2 and ERK activity collaborate in promoting LMW-AR expression we examined the calpain 2, calpastatin and pERK levels in 6 of 13 tumor samples previously analyzed for the expression of the LMW-AR. Three of the thirteen samples that had the highest levels LMW-AR (01, 31 and 94) and three that had low levels of LMW-AR (21, 25, and 28) were used in the analysis (Figure 5B). The expression of LMW-AR was defined as percent of total. Interestingly the levels of the endogenous calpain inhibitor calpastatin was variable and was higher in sample 21 and 25, which has lower levels of LMW-AR and lowest in Sample 01. Samples 01 and 31 had high levels of pERK (Figure 5C). The remaining samples had low pERK levels. Therefore, the three samples that had the highest LMW-AR had high levels of pERK or a high amount of calpain 2. Conversely, samples that had low LMW-AR levels had little pERK and had elevated calpastatin levels. This limited analysis suggests that in human tumors an increased ratio of calpain to calpastatin and increased ERK activity, in concert contribute to increased LMW-AR expression.

The LMW-AR binds to the chromosomal binding sites in the absence of androgen in Rv1 cells

Previous studies reported that deletion of the LBD resulted in the translocation of the AR into the nucleus in the absence of androgen [19, 31]. Therefore we analyzed the cellular location of the LMW-AR in the nuclear and cytosolic fractions of Rv1 and R1 cells proliferating the presence and absence of androgen (Figure 6A). In R1 cells the predominant form of the AR in the nucleus in the presence of androgen is the FL-AR. In the absence of androgen the nuclear fraction contains substantially higher amount of the LMW-AR (~60%). In the cytosolic fraction the AR is almost exclusively full length. In Rv1 cells in the presence of androgen, the FL-AR and LMW-AR are present in the nucleus. The FL-AR is more abundant in the cytosol, whereas the LMW-AR is more abundant in the nucleus. Notably, in the absence of androgen the Rv1 nuclear fraction consists predominantly (~90%) of the LMW-AR. Therefore, we performed ChIP-on-chip analysis on Rv1 cells proliferating in androgen-depleted medium to investigate the potential LMW-AR chromosomal binding sites. The same analysis was conducted on Rv1 cells treated with 10nM DHT for 2hr and in R1 cells treated in the same manner. The study used the Human Promoter 1.0R Array (Affymetrix). This oligonucleotide (25-mer)-based, high-density tiling array covers 25,500 promoters with probe sets spanning approximately 10 kb of genomic content per gene (7.5 kb upstream and 2.45 kb downstream of the transcriptional start site) and at a resolution of 35 bp.

Analysis of the ChIP-on-chip data revealed 128 binding sites ($FDR \leq 0.05$) in Rv1 cells proliferating in androgen-depleted media (Table 1). Furthermore, the 128 sites were also present in the total of 2021 binding sites identified in Rv1 cells treated with 10nM DHT for 2hrs using the same criteria (i.e. $FDR \leq 0.05$) (Figure 6B, 6C). A closer examination of these 128

binding sites revealed that 20% of the sites showed exactly the same start and end position in the absence or presence of DHT. The remainder (80%) were within the range of ~35-1000bp upstream of the start position or downstream of the end position. Furthermore, the addition of androgen induced modest [1 going to 2] enrichment of AR binding to the sequence adjacent (within 50Kb) to 46 sites (46/128=36%), and high enrichment [3 or more] to the sequence adjacent to 14 sites (14/128=11%). Addition of androgen did not cause enrichment in the AR binding to the rest 68 sites (68/128=53%). Addition of androgen also resulted in the AR binding to sites that were not bound in the absence of androgen, indicating the requirement of the FL-AR for binding to specific sequences.

Next we compared AR binding in Rv1 and R1 cells cultured in androgen depleted media. Analysis of the ChIP-on-chip data obtained from R1 cells failed to reveal binding sites that were statistically significant ($FDR \leq 0.05$). Due to the low level of the AR (both FL- and LMW-AR) in the nucleus of R1 cells proliferating in androgen depleted media, the assay may not be sensitive enough to detect binding that reaches the threshold of statistical significance. Nevertheless, the examination of the best potential binding sites provided by Cisgenome showed that 15 binding sites overlapped with the binding sites identified Rv1 cells (Table 1 labeled with *). Furthermore, all these 15 sites were identified as statistical significant ($FDR \leq 0.05$) binding sites in R1 cells treated with DHT for 2hr (Figure 6B).

We analyzed the 128 binding sites to determine whether the LMW-AR binds to the established consensus AR response element (ARE). Wang et al., [25] reported that, in LNCaP cells treated with DHT, only 10% of the AR binding regions had a canonical class 1 ARE (AGAACAAnnTGTCT) binding motif when two positions were allowed to vary from the palindromic consensus with 3 nucleotide spacing. They also found that 78% of the binding regions contained the AR binding half-site motif (AGAACA). In this study, using the similar motif mapping algorithm, we found 6% (8/128) of the LMW-AR binding sites contained the typical ARE (Table 2) and 48% contained the AR half-site motif. This indicates that, similar to the FL-AR in LNCaP cells, the LMW-AR predominantly binds to non-canonical AREs. Likewise, analysis of the 2021 binding sites identified in DHT treated Rv1 cells showed only 4% (86/2021) of the sites had the canonical ARE and 35% (700/2021) had the AR half-site motif (Figure 6D).

Further analysis of the 128 LMW-AR binding sites identified a total of 118 genes that were closest to the AR binding site (Table 1). Only 20% of the LMW-AR chromosomal binding sites were located within 2Kb up- or down-stream from the transcription start sites (Table 1). Notably, about 20% of the binding sites were more than 10kb up-stream of the transcriptional start site and 9% of the sites were more than 10kb down-stream of the transcriptional end site. This result is consistent with other reports that in LNCaP cells the majority of the AR binding sites are far away from the androgen-regulated genes [25, 26]. Interestingly, several genes (CGI-115, EPHX1, RGPD5, LPP, RHOH, MAT2B, CYP3A43, ANKRD20A3, TMEM60 and GOLGA8G) had two sites bound by the LMW-AR, and in all of the cases except (RGPD5) the two binding sites in each gene were within close vicinity (35 up to 4551bp apart).

The expression profiles of genes adjacent to LMW-AR binding sites

To correlate AR binding to gene expression we examined the gene expression profiles of Rv1 cells proliferating in androgen-depleted media and cell stimulated for 2 hours with 10 nM of DHT, conditions that were identical to conditions used to the ChIP-on-chip studies. The Affymetrix HG-U133 Plus2.0 Gene Chip microarray analysis was conducted in duplicates. We chose the two hour time point to identify transcripts that are most likely to be direct AR targets. Analysis of the microarray data identified a total of 688 genes differentially expressed (fold change ≥ 1.5 ; $P \leq 0.05$) in Rv1 cells in response to DHT in 2hr. Of the 118 closest genes identified in the ChIP-on-chip study of AR binding in the absence of androgen, we found 6 genes (CDKN1B/p27, FABP7, IL-6R, KRIT1, SMA4 and UGT2B15) showed differential

expression in response to DHT (Figure 7A). It has been reported that CDKN1B/p27 and UGT2B15 are androgen-responsive genes [36, 37]. Interestingly, a significant enrichment of AR binding sites was observed at CDKN1B/p27 gene locus, which corresponded with the up-regulation of its expression 2hr post DHT addition. When the analysis included the neighbor genes near the 128 sites, 13 (13/128=10%) were differentially regulated by androgen. Some of the genes were over 50,000 bp from the AR binding site. When the criteria for identifying androgen-regulated genes were relaxed (fold change ≥ 1.3 ; $P \leq 0.10$), 56 (56/128=44%) of the sites were associated with genes that were androgen regulated. This suggests that for some genes LMW-AR binding in the absence of androgens is not functional or not sufficient and FL-AR is required for their maximal gene regulation.

To further investigate the role of LMW-AR in gene regulation, the expression of several closest genes was analyzed in the absence of androgen following treatment with calpeptin for 48hr. Since treatment with calpeptin reduces LMW-AR expression and the amount of LMW-AR present in the nucleus (Figure 7B), this allows us to study the transcriptional regulation of genes adjacent to the potential LMW-AR binding sites. We examined the effect of LMW-AR inhibition on the expression of the above six closest genes (CDKN1B/p27, FABP7, IL-6R, KRIT1, SMA4 and UGT2B15) that showed differential expression after adding DHT for 2hr. Varied responses to the inhibition of LMW-AR were observed (Figure 7A). The expression of UGT2B15 was down-regulated after adding DHT. Interestingly, inhibition of LMW-AR also significantly reduced their expression, indicating that LMW-AR might function as an activator whereas FL-AR functions as a repressor of the gene. The expression of IL-6R, on the other hand, was elevated after adding DHT. Inhibition of LMW-AR also significantly enhanced its expression, indicating that LMW-AR might function as a repressor while the FL-AR an activator of the gene. Addition of DHT strongly up-regulated the expression of FABP7 and SMA4 (Figure 7A). Inhibition of LMW-AR showed slightly reduction on their expression, indicating that LMW-AR acts like FL-AR as an activator of the genes, but much weaker than FL-AR. While modestly up-regulated by FL-AR after adding DHT, no effect was observed on the expression of CDKN1B/p27 and KRIT1 when LMW-AR was inhibited (Figure 7A), indicating that LMW-AR binding might be non-functional.

Since our preliminary studies suggested that at least half of the hinge domain was removed on the LMW-AR (unpublished), we hypothesized that the failure to interact with the hinge region interacting co-regulators contributed to the functional differences between FL-AR and LMW-AR. Filamin A has been reported to repress AR-dependent transcription by interacting with hinge domain [38]. We analyzed the endogenous gene expression of UGT2B15 in DHT for 2hr or in the absence of androgen following siRNA-mediated silencing of filamin A. As shown in Figure 7C, anti-filamin A siRNA reduced its mRNA level to 11%. Silencing of filamin A expression relieved repression of UGT2B15 in the presence of DHT (Figure 7C: 'siRNA control AD-' vs. 'siRNA control DHT 2hr' and 'FLN siRNA DHT 2hr'), indicating that filamin A is the co-repressor of FL-AR in the suppression of the gene. Silencing of filamin A in the absence of androgen, on the other hand, showed no effect on the expression of UGT2B15 (Figure 7C: 'siRNA control AD-' vs. 'FLN siRNA AD-'), indicating that the regulation activity of LMW-AR is not affected by filamin A. This suggests that the difference in their interaction with co-regulator filamin A contributes to the different transcriptional outcome of FL- and LMW-AR.

Key Research Accomplishments

In current study, we showed that:

- Calpain 2 also plays a role in the generation of the LMW-AR in R1 cells.
- Two distinct mechanisms resulting in elevated levels of LMW-AR by proteolysis. Rv1 cells express low levels of calpain 2 and show low calpain protease activity. Nevertheless, the Rv1 AR is highly sensitive to calpain proteolysis *in vitro* and *in vivo* due to its insertion mutation. On the other hand, R1 cells express high levels of calpain 2 and have high levels of the calpain 2 protease activity, resulting in the proteolysis of the AR.
- Ras-Raf-MEK-ERK signaling pathway regulates the levels of the expression of the LMW forms of AR in Rv1 and R1 cells. Inhibition of ERK phosphorylation by a MEK inhibitor reduces ERK phosphorylation and reduces the expression of the LMW forms. Conversely, activating the Ras-Raf-Mek-ERK by TPA activation of protein kinase C (PKC) increases ERK phosphorylation and the expression of the LMW-AR in both cell types.
- 128 previous unknown binding sites by LMW-AR in Rv1 cells in the absence of androgen. Consistent with others finding, only 6% of the binding sites contain canonical ARE motif and only 20% were located within 2Kb up- or down-stream of the transcriptional start site of the adjacent genes.
- A subset of genes adjacent to the LMW-AR binding sites were differentially expressed in response to the stimulation of DHT for 2hr, indicating the requirement of FL-AR for their maximal transcriptional regulation.
- Some genes were transcriptionally regulated by both LMW-AR and FL-AR, but in an different manner.

Reportable Outcomes

We have submitted a manuscript (title: Erk Regulates Calpain2 Induced Androgen Receptor Proteolysis in CWR22 Relapsed Prostate Tumor Cell Lines) to JBC.

The author Honglin Chen obtained her Ph.D. degree in June, 2009.

Conclusions

Androgen ablation therapy is effective in treating androgen-dependent prostate tumors; however, tumors that can proliferate in castrate levels of androgen eventually arise. We previously reported that in CWR22Rv1 (Rv1) cells, the protease calpain 2 can cleave the androgen receptor (AR) into a constitutively active ~80 KDa low molecular weight (LMW) form. In this study, we further dissect the mechanisms that produce the AR LMW forms using Rv1 cells and the related CWR22-R1 (R1) cells. The 39 a.a. insertional mutation in Rv1 cells sensitizes this AR (E3DM-AR) calpain 2 proteolysis. R1 cells encode the same AR molecule as the parental CWR22 xenograft. Using anti-calpain 2 siRNA and calpeptin, we find that calpain 2 plays a role in the generation of the LMW-AR in R1 cells. Furthermore, LMW-AR expression is regulated by the activation of calpain 2 by Extracellular Signal-Regulated Kinases 1/2 (ERK). Inhibition of ERK phosphorylation or siRNA-mediate decrease of ERK expression reduces LMW-AR levels in R1 cells. Conversely, activation of the MAPK pathway and increased ERK phosphorylation results in increased levels of LMW-AR. Finally, analyses of human tumor samples found that LMW-AR levels are higher in tumors that have an increased calpain/calpastatin ratio and/or increased levels of phospho-ERK (pERK), suggesting that a higher calpain/calpastatin ratio collaborates with activation of the MAP kinase pathway to promote the generation of the LMW-AR. Furthermore, cellular localization analysis of AR shows that the LMW-AR is the predominant form (~90%) present in the nucleus in Rv1 cells cultured in the absence of androgen, allowing us to study the chromosomal binding sites of LMW-AR using chromatin immunoprecipitation (ChIP) combined with DNA microarray analysis (ChIP-on-chip). Using a human promoter array, a total of 128 potential LMW-AR chromosomal binding sites are identified in the absence of androgen and they are also present in the presence of androgen. We find that the majority of the binding sites contain no AR-responsive elements (AREs) and are distant (>2kb) from the transcriptional start sites. Corresponding expression array studies identify that only a subset of genes in the vicinity of LMW-AR binding sites respond to the stimulation of dihydrotestosterone (DHT). Moreover, quantitative RT-PCR analysis shows that LMW-AR can transcriptoinally regulate certain genes in a different manner as full-length (FL) AR.

References

1. Chen, C.D., et al., *Molecular determinants of resistance to antiandrogen therapy*. Nat Med, 2004. **10**(1): p. 33-9.
2. Gregory, C.W., et al., *A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy*. Cancer Res, 2001. **61**(11): p. 4315-9.
3. Gregory, C.W., et al., *Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft*. Endocrinology, 1999. **140**(5): p. 2372-81.
4. Ruizeveld de Winter, J.A., et al., *Androgen receptor expression in human tissues: an immunohistochemical study*. J Histochem Cytochem, 1991. **39**(7): p. 927-36.
5. Xia, L., et al., *Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells*. J Biol Chem, 2002. **277**(38): p. 35422-33.
6. Shang, Y., M. Myers, and M. Brown, *Formation of the androgen receptor transcription complex*. Mol Cell, 2002. **9**(3): p. 601-10.
7. Taplin, M.E. and S.P. Balk, *Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence*. J Cell Biochem, 2004. **91**(3): p. 483-90.
8. Berrevoets, C.A., A. Umar, and A.O. Brinkmann, *Antiandrogens: selective androgen receptor modulators*. Mol Cell Endocrinol, 2002. **198**(1-2): p. 97-103.
9. Louie, M.C., et al., *Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex*. Proc Natl Acad Sci U S A, 2003. **100**(5): p. 2226-30.
10. Visakorpi, T., et al., *In vivo amplification of the androgen receptor gene and progression of human prostate cancer*. Nat Genet, 1995. **9**(4): p. 401-6.
11. Linja, M.J., et al., *Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer*. Cancer Res, 2001. **61**(9): p. 3550-5.
12. Marcelli, M., et al., *Androgen receptor mutations in prostate cancer*. Cancer Res, 2000. **60**(4): p. 944-9.
13. Tilley, W.D., et al., *Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence*. Clin Cancer Res, 1996. **2**(2): p. 277-85.
14. Veldscholte, J., et al., *A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens*. Biochem Biophys Res Commun, 1990. **173**(2): p. 534-40.
15. Wilding, G., M. Chen, and E.P. Gelmann, *Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens*. Prostate, 1989. **14**(2): p. 103-15.
16. Zhao, X.Y., et al., *Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor*. Nat Med, 2000. **6**(6): p. 703-6.
17. Tan, J., et al., *Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells*. Mol Endocrinol, 1997. **11**(4): p. 450-9.
18. Jenster, G., et al., *Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization*. Mol Endocrinol, 1991. **5**(10): p. 1396-404.

19. Ceraline, J., et al., *Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer*. Int J Cancer, 2004. **108**(1): p. 152-7.
20. Pelley, R.P., et al., *Calmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells*. Cancer Res, 2006. **66**(24): p. 11754-62.
21. Libertini, S.J., et al., *Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence*. Cancer Res, 2007. **67**(19): p. 9001-5.
22. Yang, H., et al., *Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells*. J Cell Physiol, 2008. **217**(3): p. 569-76.
23. Bernstein, B.E., et al., *Genomic maps and comparative analysis of histone modifications in human and mouse*. Cell, 2005. **120**(2): p. 169-81.
24. Cawley, S., et al., *Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs*. Cell, 2004. **116**(4): p. 499-509.
25. Wang, Q., et al., *A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth*. Mol Cell, 2007. **27**(3): p. 380-92.
26. Takayama, K., et al., *Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis*. Oncogene, 2007. **26**(30): p. 4453-63.
27. Carroll, J.S., et al., *Genome-wide analysis of estrogen receptor binding sites*. Nat Genet, 2006. **38**(11): p. 1289-97.
28. Wainstein, M.A., et al., *CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma*. Cancer Res, 1994. **54**(23): p. 6049-52.
29. Tepper, C.G., et al., *Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line*. Cancer Res, 2002. **62**(22): p. 6606-14.
30. Gregory, C.W., et al., *Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen*. Cancer Res, 2001. **61**(7): p. 2892-8.
31. Gregory, C.W., B. He, and E.M. Wilson, *The putative androgen receptor-A form results from in vitro proteolysis*. J Mol Endocrinol, 2001. **27**(3): p. 309-19.
32. Libertini, S.J., et al., *Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype*. Cancer Res, 2005. **65**(23): p. 10700-8.
33. Zhang, W., R.D. Lane, and R.L. Mellgren, *The major calpain isozymes are long-lived proteins. Design of an antisense strategy for calpain depletion in cultured cells*. J Biol Chem, 1996. **271**(31): p. 18825-30.
34. Glading, A., et al., *Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway*. J Biol Chem, 2000. **275**(4): p. 2390-8.
35. Lee, H.W., et al., *Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B*. J Biol Chem, 2002. **277**(36): p. 32624-31.
36. Chen, Y., et al., *Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats*. Cell Growth Differ, 1996. **7**(11): p. 1571-8.

37. Bao, B.Y., et al., *Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes*. Prostate, 2008. **68**(8): p. 839-48.
38. Loy, C.J., K.S. Sim, and E.L. Yong, *Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions*. Proc Natl Acad Sci U S A, 2003. **100**(8): p. 4562-7.

Supporting Data

Fig.1. Rv1 and R1 cells proliferate in castrate levels of androgen. A. R1 and Rv1 cells proliferating in the presence of androgen (Ad+) are less refractile than cells in androgen depleted media (Ad-). B. AR expression is greater in R1 than in Rv1 cells, but the FL and LMW AR expressed in R1 cells is slightly smaller than that expressed in Rv1 cells. C. R1 and Rv1 cells proliferate in castrate levels of androgen, but proliferation is slightly greater in the presence of androgen. Androgen depletion inhibits LNCaP proliferation. D. Rv1 and R1 cells proliferate in the presence of 10uM Casodex.

Fig 2. Calpain expression and activity in prostate derived cells. A. Inhibition of calpain activity in R1 cells with calpeptin (60uM) for 48 h decreases the expression of the LMW-AR. B. Top panel: Western blot analysis of calpain 2 expression in non-transformed and tumor prostate cells. Bottom panel: Western blot analysis of calpastatin levels in non-transformed and tumor cells. GAPDH served as a loading control. C. Calpain-dependent proteolysis of FAK from a 120 KDa form to 90 KDa and ultimately smaller forms is indicative of calpain activity. FAK proteolysis is greater in R1 than in Rv1 cells and is greater in both cells in the absence of androgens. D. Calpain 2 siRNA down-regulated calpain 2 protein levels of calpain 2 144 h post transfection in R1 cells. The down-regulation of calpain 2 expression by anti-calpain 2 siRNA reduced the LMW-AR and calpain-dependent proteolysis of FAK. E. Expression of CLDN4 in R1 cells culture in androgen depleted media, following a 2 h stimulation with DHT and a 24 h treatment with 60uM calpeptin was assessed by real time PCR. CLDN4 expression was standardized to GAPDH.

Fig 3. Transient expression of wt and E3DM-AR cDNA in PC3 cells. A. Transfection of PC3 cells with wt or E3DM-AR cDNA results in the expression of FL and LMW (denoted by arrows and brackets) forms of AR. The 3 nonspecific (NS) bands at ~ 80 KDa present in the non-transfected PC3 cells serve as markers (denoted by dots). The FL and LMW forms expressed in cells transfected with the E3DM-AR are slightly larger. B. Extracts prepared from PC3 cells transfected with wt or E3DM-AR were treated with 1M CaCl₂ to activate calpain activity. The E3DM-AR is degraded more rapidly than the WT AR. (Compare lane 1 and 6; 2 and 7; 4 and 9).

Fig 4. Inhibition of ERK phosphorylation reduces the expression of the LMW-AR. A. Western blot analysis of ERK expression in non-transformed and tumor-derived cells lines. B. The pERK levels are higher in R1 than Rv1 cells in the presence or absence of androgen. C. R1 cells were treated with 20 uM of the MEK inhibitor U0126 (I) or vehicle (C) for 24 or 48 hours in the presence or absence of androgens. The top portion of the blot shown in top panel was used to detect the expression of AR. Inhibition of ERK phosphorylation reduced the expression of the LMW-AR. The arrows denote the FL and ~ 80 KDa LMW-AR. D. ERK specific siRNA reduced the expression of pERK and the levels of LMW AR.

Fig 5. ERK activation and calpain/calpastatin ratios collaborate to promote expression of the LMW AR. A. Treatment of R1 and Rv1 cells with TPA (10 nM) for 1 and 2 hours increases the expression of the LMW-AR forms (top panel). Control cells were treated with DMSO. The bottom panel shows that TPA treatment increases pERK levels. B. Higher calpain/calpastatin and pERK levels together correlate with higher expression of LMW AR in tumor samples. C. Quantitation of the expression data in panel B. The calpain/calpastatin ratios multiplied by levels of pERK are significantly higher in samples with elevated levels of LMW-AR.

Figure 6. The identification of the potential chromosomal binding sites of LMW AR in Rv1 cells by ChIP-on-chip assay. A. The cytoplasmic and nuclear extracts showed the cellular location of the FL- and LMW-AR in Rv1 and R1 cells in the absence and presence of androgen. B. The diagram showed the number of the overlapping chromosomal binding sites identified in Rv1 cells cultured in the absence of androgen (orange) or stimulated with DHT for 2hr (yellow) and in R1 cells stimulated with DHT for 2hr (yellow). C. An extensive view of the binding sites in chromosome 12 identified in Rv1 cells cultured in the absence of androgen (Rv1-AD-) or stimulated by DHT for 2hr (Rv1_AD+) (top panel). A closer view of the binding sites around the gene CDKN1B in Rv1 cells cultured in the absence androgen or stimulated by DHT for 2hr (bottom panel). The graph was generated using UCSC genome browser. D. A pie chart showing the distribution of the binding motifs of AR in the absence of androgen (AD-) or in response to DHT for 2hr.

Figure 7. Transcriptional regulation of LMW-AR in Rv1 cells. (A). Real-time PCR analysis of LMW-AR bound genes in response to DHT stimulation or inhibition of LMW-AR expression by calpeptin treatment. Rv1 cells proliferated in the absence of androgen were incubated with 10nM DHT for 2hr or 40uM calpeptin for 48hr. (B). Calpeptin treatment reduced the amount of LMW-AR in the Rv1 nucleus extract. Rv1 cells proliferated in the absence of androgen were treated with 40uM calpeptin for 48hr. Cells were harvested, fractionated and subject to Western blot. The band is the LMW-AR and FL-AR is invisible on this blot. (C). Real-time PCR analysis of Filamin A and UGT2B15. Rv1 cells proliferated in the absence of androgen were treated with anti-filamin A siRNA or control siRNA for 72hr, then harvested for RNA extraction, or treated with 10nM DHT for 2hr and then harvested for RNA extraction.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Table 1. The list of potential LMW-AR chromosomal binding sites identified by ChIP-on-chip in Rv1 cells cultured in androgen depleted medium.

chromosome	start	end	FDR	Closest gene	distance_to_TSS	location
chr1	16864805	16865837	0.05	NBPF1	-52753	TSS_upstream
	22136758	22137152	0.00	HSPG2	-622	TSS_upstream
	* 42578210	42578867	0.05	FOXJ3	-5049	TSS_upstream
	85111676	85111897	0.05	EDG7	-7357	TSS_upstream
	152657272	152657555	0.04	IL6R	13121	intron
	* 159635314	159635709	0.05	C1orf192	-31224	TSS_upstream
	161110301	161110770	0.05	C1orf110	-5307	TSS_upstream
						TES_downstream
	205563333	205563694	0.00	CD55	234307	m
	208025311	208026089	0.04	C1orf74	-1188	TSS_upstream
	216522748	216523246	0.00	CGI-115	-2277	TSS_upstream
	216524107	216524509	0.05	CGI-115	-966	TSS_upstream
	224074724	224075447	0.02	EPHX1	-4513	TSS_upstream
	224076182	224076536	0.03	EPHX1	-3239	TSS_upstream
	226930302	226930964	0.05	RHOU	-6858	TSS_upstream
	227474815	227475660	0.05	RAB4A	1736	intron
	227687485	227687790	0.05	NUP133	23073	intron
chr2	9068246	9068784	0.05	MBOAT2	-7189	TSS_upstream
	* 61096462	61097660	0.00	FLJ32312 LOC9034	1650	5'UTR
	96709406	96710018	0.02	2	-15208	TSS_upstream
	102100298	102100788	0.05	IL1R1	-36290	TSS_upstream
	109906570	109906985	0.02	RGPD7	-846	TSS_upstream
	110771915	110772458	0.02	RGPD5	-282326	TSS_upstream
	111053390	111053866	0.05	RGPD5	-851	TSS_upstream
	* 121756809	121757420	0.05	TFCP2L1	2130	intron
	135313183	135314419	0.00	ACMSD	1146	intron
	217188354	217189045	0.05	IGFBP2	-17672	TSS_upstream
	238433717	238434904	0.00	RAMP1	1385	intron
	241681282	241681890	0.02	MTERFD2	8810	3'UTR
chr3	95228036	95228573	0.05	STX19	1839	5'UTR
	155525085	155526261	0.00	DHX36	-709	TSS_upstream
	170972672	170973372	0.00	MYNN	-524	TSS_upstream
	184090480	184091149	0.00	ATP11B	96830	intron
	189407063	189407672	0.00	LPP	-6047	TSS_upstream
	189411186	189411946	0.00	LPP	-1848	TSS_upstream
chr4	39868356	39869125	0.02	RHOH	-6256	TSS_upstream
	39869633	39869883	0.05	RHOH	-5238	TSS_upstream
	57242033	57242991	0.05	HOP	-191	TSS_upstream
	* 69116609	69117122	0.05	UGT2B17	-26	TSS_upstream
	* 69570641	69571326	0.02	UGT2B15	-5	TSS_upstream
	71417985	71418195	0.05	UNQ689	-796	TSS_upstream

	83631386	83632082	0.02	MASA LOC1501	60948	TES_downstream
	104160587	104161189	0.00	59	-564	TSS_upstream
	116253672	116254863	0.05	NDST4	213	5'UTR
chr5	17358364	17359521	0.00	BASP1 LOC3892	88193	TES_downstream
	43075976	43077397	0.05	89	-589	TSS_upstream
	69043534	69043826	0.05	SMA4	-32839	TSS_upstream
	69174442	69174858	0.05	GUSBP1	-60708	TSS_upstream
	71046170	71046891	0.00	CARTPT	-4219	TSS_upstream
	95003096	95003955	0.00	RFESD	-4816	TSS_upstream
	132412520	132413483	0.00	HSPA4	-2559	TSS_upstream
	133356892	133357581	0.05	VDAC1 MGC2398	11095	5'UTR
*	147271350	147271821	0.05	5	-5328	TSS_upstream
	165140913	165141810	0.05	MAT2B	2278553	TES_downstream
	165145723	165146101	0.00	MAT2B	2283104	TES_downstream
	177409706	177410694	0.00	PROP1	-54352	TSS_upstream
chr6	27555314	27555674	0.02	ZNF184	-6637	TSS_upstream
	32481685	32482038	0.05	BTNL2	1016	intron
	35802763	35803273	0.02	C6orf81	-9818	TSS_upstream
	123134867	123135269	0.05	FABP7	-7276	TSS_upstream
chr7	77258666	77258951	0.00	TMEM60	6874	TES_downstream
	77259297	77259870	0.00	TMEM60	6099	TES_downstream
	86810485	86812436	0.05	CROT	-1486	TSS_upstream
	90173344	90174014	0.05	PFTK1	-2968	TSS_upstream
	91720528	91720823	0.02	KRIT1	-7512	TSS_upstream
	94789986	94790898	0.05	PON1	1337	intron
	99262534	99262861	0.02	CYP3A43	-874	TSS_upstream
	99263324	99263899	0.00	CYP3A43	40	5'UTR
chr8	1908276	1908755	0.04	KBTBD11	-935	TSS_upstream
	1985866	1986424	0.05	MYOM2	5491	5'UTR
	32618295	32618812	0.02	NRG1	93259	intron
*	62764856	62765634	0.02	ASPH	-327	TSS_upstream
	81155377	81156130	0.05	TPD52	-189	TSS_upstream
	92016257	92016819	0.02	EFCBP1	143585	intron
	95635315	95635625	0.05	KIAA1429	-607	TSS_upstream
	104842195	104842405	0.02	RIMS2	-58375	TSS_upstream
	134408137	134408683	0.05	NDRG1	-29731	TSS_upstream
chr9	458522	459780	0.00	DOCK8 MGC2188	196104	TES_downstream
	42014216	42015102	0.00	1 ANKRD20	-69629	TSS_upstream
	42473311	42473672	0.05	A3	115193	TES_downstream
	43008156	43008569	0.05	ANKRD20	650064	TES_downstream

			A3	m	
	83490582	83491814	0.05	TLE1	2217 intron
*	127099076	127099337	0.05	GAPVD1	35275 5'UTR
	130683610	130683946	0.05	CCBL1	396 5'UTR
chr10	75005198	75007594	0.00	USP54	-23293 TSS_upstream
	88842056	88843108	0.04	GLUD1	2020 intron
	111752538	111753211	0.05	ADD3	-2841 TSS_upstream
	114110373	114110898	0.02	ACSL5	-13270 TSS_upstream
chr11	76424867	76425442	0.04	B3GNT6	2047 5'UTR
	101688751	101689123	0.05	BIRC3	-4466 TSS_upstream
	110679133	110682583	0.00	FLJ45803 PAFAH1B	-5110 TSS_upstream
	116515530	116515766	0.00	2	-4601 TSS_upstream
chr12	12762638	12763601	0.05	CDKN1B	1544 exon
	12921346	12922113	0.05	GPRC5A PRICKLE	-13493 TSS_upstream
	41273916	41274369	0.05	1	-4398 TSS_upstream
	45472464	45473769	0.00	SLC38A4	32885 exon
	69324316	69324768	0.02	PTPRR	110089 intron
*	69842894	69844074	0.02	TSPAN8	452 intron
	89919368	89919774	0.05	DSPG3	3362 intron
*	100393303	100394366	0.00	SPIC	-953 TSS_upstream
	102787842	102789518	0.00	NT5DC3	-29576 TSS_upstream
	108233254	108234362	0.00	FOXN4	-2401 TSS_upstream
chr13					
*	27089576	27090358	0.00	LNK2	2571 5'UTR
	31417733	31418816	0.02	FRY	-85162 TSS_upstream
	48871900	48872719	0.05	CAB39L	1190 5'UTR
chr14	52082233	52082434	0.05	KIAA1344	6629 5'UTR
					TES_downstream
	57128860	57129691	0.05	C14orf105	323896 m
	67066319	67067360	0.00	PLEKHH1	-2921 TSS_upstream
	77235294	77235817	0.02	ALKBH1	8553 intron
chr15	20286282	20286797	0.04	TUBGCP5	-98403 TSS_upstream
					TES_downstream
	21131612	21131948	0.00	FLJ36144 GOLGA8	111702 m
	26277642	26277943	0.05	G GOLGA8	-19612 TSS_upstream
	26596571	26596904	0.05	G	-19580 TSS_upstream
	40350094	40350898	0.02	TMEM87A	2426 intron
*	66901192	66901763	0.02	ANP32A	-1201 TSS_upstream
*	89205500	89205991	0.00	FURIN	-7143 TSS_upstream
chr16	53518414	53519450	0.02	IRX5	-3679 TSS_upstream
chr17					
*	7998727	7999908	0.00	PER1	-2891 TSS_upstream
	19486254	19486717	0.05	ALDH3A2	-6170 TSS_upstream
chr18	19518446	19519169	0.00	LAMA3	-4752 TSS_upstream
	46811264	46812019	0.02	SMAD4	1031 5'UTR
					TES_downstream
chr20	31242786	31243701	0.00	C20orf70	23623 m

	57966260	57966718	0.05	CDH26	-387	TSS_upstream
chr22	14653344	14654277	0.00	ACTBL1	14126	3'UTR
	19829248	19829710	0.05	FLJ42953	42175	TES_downstrea
	19949347	19950008	0.05	GGT2	-39096	m
	43964814	43965717	0.00	C22orf9	21745	TSS_upstream
chrX	106756502	106757108	0.02	PRPS1	-1609	TES_downstrea
	128623040	128623977	0.00	APLN	-6914	m
						TSS_upstream